New data highlights that pertuzumab (Perjeta) can extend survival for women with HER 2 positive advanced breast cancer by 15.7 months more than standard of care. Carolyn Rogers Clinical Nurse Specialist at Breast Cancer Care said:

“We were very disappointed when draft guidance issued by NICE last year did not recommend the use of Perjeta. These new findings highlight the significant progress being made in treating advanced breast cancer and provide further data that Perjeta can extend life for women living with HER 2 positive advanced breast cancer.

“So it is devastating for women living with this type of cancer to know that a treatment which can prolong their survival is still not widely available. Though it is available through the Cancer Drugs Fund this is not an adequate solution as this scheme is due to terminate in 2016 and is only available to people in England.”